Holen Sie sich die Stockscreener-App
14.13
0.21%
-0.03
Vorhandelsmarkt:
14.11
-0.02
-0.14%
Schlusskurs vom Vortag:
$14.16
Offen:
$14.23
24-Stunden-Volumen:
1.32M
Relative Volume:
0.88
Marktkapitalisierung:
$2.01B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.61M
KGV:
-43.68
EPS:
-0.3235
Netto-Cashflow:
$-45.40M
1W Leistung:
-0.49%
1M Leistung:
-4.53%
6M Leistung:
+28.57%
1J Leistung:
+134.33%
1-Tages-Spanne:
$14.12
$14.49
1-Wochen-Bereich:
$13.12
$14.49
52-Wochen-Spanne:
$5.3801
$16.12
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.13 | 2.01B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - MSN
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Quantisnow
TRVI Reiterated by Needham -- Price Target Maintained at $23 - GuruFocus
TRVI News | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill
Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal u - AD HOC NEWS
Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GuruFocus
Trevi Therapeutics, Inc. (TRVI) Analyst/Investor DaySlideshow (NASDAQ:TRVI) 2026-05-15 - Seeking Alpha
Trevi Therapeutics, Inc.Common Stock (Nasdaq:TRVI) Stock Quote - FinancialContent
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
TradingKey - TradingKey
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
TRVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - sharewise.com
Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Equities Analysts Offer Predictions for TRVI Q2 Earnings - MarketBeat
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech With 59.82% Potential Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21 - Moomoo
NEA stake in Trevi now 10.5% on share increase (TRVI) - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Research Analysts Set Expectations for TRVI FY2030 Earnings - MarketBeat
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 - Yahoo Finance
FMR LLC shows 6.3% stake in Trevi Therapeutics (NASDAQ: TRVI) - Stock Titan
B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating - marketscreener.com
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
MSN Money - MSN
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 - Investing.com
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 By Investing.com - Investing.com Canada
Trevi Therapeutics Q1 Earnings Call Highlights - MarketBeat
Trevi Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com UK
TRVI: Cash runway into 2030 supports multiple advancing chronic cough trials and new patent coverage - TradingView
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress By Investing.com - Investing.com South Africa
Trevi Therapeutics Q1 net loss widens as R&D costs rise - TradingView
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Q1 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan
Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan
Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BRIEF-Trevi Therapeutics Q1 Net Income USD -13.192 Million - TradingView
Trevi Therapeutics raises $162M, extends cash runway to 2030, advances chronic cough drug trials. - Pluang
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):